{"entity":{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","aka":[],"tldr":"A phase 2 trial of Darovasertib in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.","summary":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma is a phase 2 interventional study registered as NCT05907954 by IDEAYA Biosciences, with 160 participants planned, started 2023-07-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Darovasertib. Conditions listed: Uveal Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05907954","url":"https://clinicaltrials.gov/study/NCT05907954"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["darovasertib"],"companies":["ideaya-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05907954","phase":"2","setting":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","sponsor":"IDEAYA Biosciences","enrolled":160,"outcomes":[]},"route":"/trials/nct05907954/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/"}],"company":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"}]}}